Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608415 | 0.94 | GAA (0.51) | GAACNR1TSPOLMNACYP3A4 | |
| SCHEMBL612631 | 0.88 | KMT2A (0.53) | GAAAURKATSPOKDM4EHPGD | |
| SCHEMBL612231 | 0.85 | KMT2A (0.46) | GAATSPOKDM4EHPGDHSD17B10 | |
| SCHEMBL610138 | 0.84 | WNT3A (0.47) | GAATSPOLMNACYP3A4KDM4E | |
| SCHEMBL610485 | 0.82 | GABRA1 (0.48) | TSPOLMNACYP3A4KDM4EALB | |
| SCHEMBL611881 | 0.82 | KDM4E (0.48) | KDM4EKMT2AMEN1 | |
| SCHEMBL611044 | 0.81 | TSPO (0.43) | CNR1TSPOLMNACYP3A4KDM4E | |
| SCHEMBL610176 | 0.81 | GAPDH (0.54) | TSPOLMNACYP3A4KDM4EHPGD | |
| SCHEMBL611982 | 0.81 | ROCK1 (0.46) | GAATSPOLMNACYP3A4KDM4E | |
| SCHEMBL611077 | 0.81 | TSPO (0.40) | GAATSPOLMNACYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | claimed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | claimed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | claimed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | claimed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | claimed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | claimed |
| US-8993562-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-8153789-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-10 | — | — | US | disclosed |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | disclosed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | disclosed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | GABRA5, GABRA1, GABRA2 | GAA 4058/4885AURKA 1073/4885CNR1 44/4885 |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | GABRA5, GABRA1, GABRA2 | GAA 4058/4885AURKA 1073/4885CNR1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.